Rising anthrax infections are driving the Anthim Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Anthrasil Market At The End Of The 2026–2030 Forecast Period?

The expansion observed during the historic period resulted from governmental biodefense initiatives, the clinical effectiveness of immune globulin therapy, the absence of alternative toxin neutralizers, national emergency readiness programs, and urgent regulatory clearances.

Growth within the forecast period is propelled by ongoing financial support for public health readiness, the enlargement of biodefense reserves, an increased emphasis on swift toxin deactivation, advancements in processing plasma-derived products, and enduring government procurement contracts.

Key developments anticipated in the forecast timeframe encompass the increasing adoption of anthrax immune globulin treatments, the broadening of multi-drug treatment approaches, greater tactical accumulation of immune globulins, heightened attention on therapies designed to neutralize toxins, and improved care strategies for anthrax in both children and adults.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19876&type=smp

What Primary Drivers Are Shaping The Development Of The Anthrasil Market?

The escalating occurrence of anthrax infections is projected to stimulate the growth of the anthrasil market. Anthrax infections originate from the bacterium Bacillus anthracis and can develop through skin contact, inhalation, or ingestion, resulting in severe symptoms that vary according to the exposure route. The growing incidence of anthrax infections is linked to factors such as increased contact with infected animals, inadequate veterinary supervision, and socio-economic obstacles that impede effective disease management and prevention. This rising incidence of anthrax infections necessitates more frequent use of anthrasil, as additional cases require effective treatments to provide immediate passive immunity and improve survival rates. For instance, in December 2023, as per a report published by the World Health Organization (WHO), a Switzerland-based health authority, suspected anthrax cases in Zambia surged from 42 between September 2022 and January 2023 to 684 by November 20, 2023, including four deaths (0.6% CFR), across 44 districts in nine of the country’s ten provinces. Therefore, the increasing prevalence of anthrax infections is a key driver for the anthrasil market.

What Segment Types Make Up The Anthrasil Market?

The anthrasil market covered in this report is segmented –

1) By Type: 60U, 100U

2) By Clinical Indication: Inhalational Anthrax, Anthrax Toxin Neutralization, Severe or Systemic Anthrax Infections, Prevention of Disease Progression in At-Risk Populations, Post-Exposure Prophylaxis (PEP)

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Other End-Users

Which Market Trends Are Creating New Opportunities In The Anthrasil Market?

Leading companies in the anthrasil market are concentrating on innovative vaccine development methodologies, such as cell-free filtrate technology, to boost efficacy, improve safety profiles, and address evolving bioterrorism threats. This cell-free filtrate technology utilizes non-living components from an avirulent strain of Bacillus anthracis to minimize the risk of adverse reactions while effectively stimulating the immune system. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company focused on developing vaccines and antibody therapeutics for infectious diseases, obtained U.S. Food and Drug Administration (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), representing a significant advance in anthrax vaccination efforts. CYFENDUS includes an adjuvant called CPG7909, which enhances the immune response, potentially leading to more potent and swift antibody production against Bacillus anthracis. The vaccine is derived from cell-free filtrates of an avirulent strain of B. anthracis, guaranteeing it contains no live or dead bacteria, which may reduce the risk of adverse reactions compared to traditional vaccines that contain whole organisms.

Who Are The Key Players Driving Competition In The Anthrasil Market?

Major companies operating in the anthrasil market are Emergent BioSolutions Inc.

Read the full anthrasil market report here:

https://www.thebusinessresearchcompany.com/report/anthrasil-global-market-report

How Does The Anthrasil Market Perform Across Major Global Regions?

North America was the largest region in the Anthrasil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrasil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anthrasil Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19876&type=smp

Browse Through More Reports Similar to the Global Anthrasil Market 2026, By The Business Research Company

Anthracite Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthracite-global-market-report

Anthracycline Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

Anthrax Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795